Evidence map›Paper›PMID 33842647›Full record

ArticleAnnals of translational medicine2021

A novel compound heterozygous mutation in ABCB4 gene in a pedigree with progressive familial intrahepatic cholestasis 3: a case report.

Jie Bai, Lu Li, Hui Liu, Shuang Liu, Li Bai, Hanbing Ning, Wenyan Song, Huaibin Zou, Xinxin Wang, Yu Chen and 2 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. [A brief talk on the diagnostic principle for inherited metabolic liver disease in adult].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jie BaiFourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You An Hospital, Capital Medical University, Beijing, China.
Lu LiFourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You An Hospital, Capital Medical University, Beijing, China.
Hui LiuDepartment of Pathology, Beijing You An Hospital, Capital Medical University, Beijing, China.
Shuang LiuBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, China.
Li BaiBeijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, China.
Hanbing NingDepartment of Digestive Diseases, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wenyan SongDepartment of Radiology, Beijing You An Hospital, Capital Medical University, Beijing, China.
Huaibin ZouFourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You An Hospital, Capital Medical University, Beijing, China.
Xinxin WangDepartment of Pathology, Beijing You An Hospital, Capital Medical University, Beijing, China.
Yu ChenFourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You An Hospital, Capital Medical University, Beijing, China.
Sujun ZhengFirst Department of Liver Disease, Beijing You An Hospital, Capital Medical University, Beijing, China.
Zhongping DuanFourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You An Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing YouAn Hospital · CNFirst Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive familial intrahepatic cholestasis (PFIC) includes a group of genetic autosomal recessive disorders that predominantly affects young children and results in early-onset progressive liver damage. Variations in

Indexed as

ABCB4case reportcompound heterozygous mutationLiver cirrhosisProgressive familial intrahepatic cholestasis (PFIC)

Identifiers

PMID33842647
PMCPMC8033375
OpenAlexW3137858774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.